Zobrazeno 1 - 10
of 49
pro vyhledávání: '"J. A. M. Raaijmakers"'
Autor:
J. A. M. Raaijmakers, J. G. C. van Hasselt, M J J Hooiveld, Jan H.M. Schellens, Gerardus W.J. Frederix, Johan L. Severens, Patrick Neven, Anke M. Hövels
Publikováno v:
European Journal of Cancer Care. 24:340-354
Currently, no country-specific metastatic breast cancer (MBC) observational costing data are available for the Netherlands and Belgium. Our aim is to describe country-specific resource use and costs of human epidermal receptor 2 (HER-2)-positive MBC
Autor:
Johan L. Severens, Gerardus W.J. Frederix, J. A. M. Raaijmakers, Alwin D. R. Huitema, Jan H.M. Schellens, Johan G. C. van Hasselt, Anke M. Hövels
Publikováno v:
Pharmacoeconomics (Print), 47-61. Adis
STARTPAGE=47;ENDPAGE=61;ISSN=1170-7690;TITLE=Pharmacoeconomics
STARTPAGE=47;ENDPAGE=61;ISSN=1170-7690;TITLE=Pharmacoeconomics
Structural uncertainty relates to differences in model structure and parameterization. For many published health economic analyses in oncology, substantial differences in model structure exist, leading to differences in analysis outcomes and potentia
Autor:
J. A. M. Raaijmakers, Jan H.M. Schellens, Anke M. Hövels, Gerardus W.J. Frederix, J. G. C. van Hasselt, Johan L. Severens
Publikováno v:
Breast Cancer Research and Treatment, 139, 489-495. Springer New York
Adequate reflection of disease progression and costs over time is essential in cost-effectiveness analyses based on health state-transition models. However, costing studies normally investigate the burden of metastatic breast cancer (MBC) without exp
Autor:
Johan L. Severens, Gerardus W.J. Frederix, Alwin D. R. Huitema, Anke M. Hövels, Jan H.M. Schellens, J. A. M. Raaijmakers, Johan G. C. van Hasselt
Publikováno v:
Medical Decision Making, 33(6), 780-792. SAGE Publishing
Introduction. Dynamic processes in cost-effectiveness analysis (CEA) are typically described using cohort simulations, which can be implemented as Markov models, or alternatively using systems of ordinary differential equations (ODEs). In the field o
Autor:
Svetlana V. Belitser, J. A. M. Raaijmakers, Anke M. Hövels, P van Bakel, Geert W.J. Frederix, RW Roberts, L. Tariq
Publikováno v:
Value in Health. 18(7)
Autor:
Svetlana V. Belitser, J. A. M. Raaijmakers, Anke M. Hövels, Rick A. Vreman, Olaf H. Klungel, Joost W Geenen
Publikováno v:
Value in Health. 20:A739
Autor:
G W J, Frederix, J L, Severens, A M, Hövels, J G C, van Hasselt, M J J, Hooiveld, P, Neven, J A M, Raaijmakers, J H M, Schellens
Publikováno v:
European journal of cancer care. 24(3)
Currently, no country-specific metastatic breast cancer (MBC) observational costing data are available for the Netherlands and Belgium. Our aim is to describe country-specific resource use and costs of human epidermal receptor 2 (HER-2)-positive MBC
Autor:
Gerardus W.J. Frederix, Anke M. Hövels, J. G. C. van Hasselt, Jan H.M. Schellens, Johan L. Severens, J. A. M. Raaijmakers
Publikováno v:
Value in Health. 16(7)
Adequate reflection of disease progression and costs over time is essential in cost-effectiveness analyses based on health state-transition models. However, costing studies normally investigate the burden of metastatic breast cancer (MBC) without exp
Autor:
Ghislaine J. M. W. van Thiel, J. A. M. Raaijmakers, Johannes J. M. van Delden, Rosemarie D. L. C. Bernabe
Publikováno v:
The American Journal of Bioethics. 9:56-58
In the article, “Assessing social risks prior to commencement of a clinical trial: Due diligence or ethical inflation,” the authors spoke of the merits of the rapid policy assessment (RPA) social r...
Autor:
Miranda Buitenhuis, Leo Koenderman, Belinda Baltus, T. B. Van Dijk, R. P. De Groot, J. A. M. Raaijmakers, Jan Willem J. Lammers, C. Vinson
Publikováno v:
Scopus-Elsevier
The eosinophil-derived neurotoxin (EDN), a member of the mammalian ribonuclease family, is found in the large specific granules of human eosinophilic leukocytes. We have investigated the role of the C/EBP transcription factor family in the regulation